Vyriad, Inc. is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases.
The company leverages engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells, advancing programs in oncolytic virotherapy, in vivo gene therapy, and gene-editing with partnerships including Regeneron and Novartis.
Leadership & Board
Current Number of Employees58
Current LinkedIn Followers5,279
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$85M
Total Amount Raised$85M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$85M
Latest Funding Amount$85M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Vyriad Inc had 58 employees as of September 14, 2026. The number of employees increased by 0 (0.00%) week-over-week.
58Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Vyriad Inc had 5,279 followers as of September 14, 2026. The number of followers increased by 19 (0.36%) week-over-week.
5,279Latest Followers Count
19(0.36%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.